Runkai Hu
Research Subjects
Research Interests
Runkai Hu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Baocheng Xie
Department of Pharmacy, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People’s Hospital), China
1 shared publication - Minyi Chen
Department of Pharmacy
1 shared publication - Ruirong He
Department of Pharmacy, The Tenth Affiliated Hospital of Southern Medical University (Dongguan People’s Hospital), Dongguan, China
1 shared publication - Shaobo Ding
Department of Pharmacy
1 shared publication - Shichun Chen
Department of Pharmacy
1 shared publication - Weichao Han
Department of Pharmacy
1 shared publication
Latest Publications
- Open Access
- 13 September 2021
- Published by Wiley in Stem Cells International
- Vol. 2021, 1-9
Clinical Efficacy and Safety of Human Mesenchymal Stem Cell Therapy for Degenerative Disc Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Degenerative disc disease (DDD) can cause severe low back pain, which will have a serious negative impact on the ability to perform daily tasks or activities. For the past few years, mesenchymal stem cell (MSC) transplantation has emerged as a promising strategy for the treatment of DDD. However, the clinical efficacy of MSC in the treatment of DDD still lacks clinical evidence and is controversial. We conducted a meta-analysis with randomized controlled trials (RCTs) to evaluate the clinical efficacy and safety of MSC transplantation in patients with DDD. We searched major databases using terms from the database’s inception through March 2021. The Cochrane bias risk assessment tool was used to assess quality. The analysis showed that MSC therapy could decrease visual analog scale (VAS) scores ( , , ) and Oswestry Disability Index (ODI) scores ( , , ). The outcomes with subgroup analysis showed that MSC therapy could decrease VAS scores in 3 months ( ), 6 months ( ), 12 months ( ), and ≥24 months ( ) and ODI scores in ≥24 months ( ). Pooled analysis showed that MSC therapy has a higher ratio of patients at most thresholds but particularly at the MIC (minimally important change) (
- 13 September 2021
- Published by Wiley in Stem Cells International
- Vol. 2021, 1-9
Open AccessClinical Efficacy and Safety of Human Mesenchymal Stem Cell Therapy for Degenerative Disc Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Degenerative disc disease (DDD) can cause severe low back pain, which will have a serious negative impact on the ability to perform daily tasks or activities. For the past few years, mesenchymal stem cell (MSC) transplantation has emerged as a promising strategy for the treatment of DDD. However, the clinical efficacy of MSC in the treatment of DDD still lacks clinical evidence and is controversial. We conducted a meta-analysis with randomized controlled trials (RCTs) to evaluate the clinical efficacy and safety of MSC transplantation in patients with DDD. We searched major databases using terms from the database’s inception through March 2021. The Cochrane bias risk assessment tool was used to assess quality. The analysis showed that MSC therapy could decrease visual analog scale (VAS) scores ( , , ) and Oswestry Disability Index (ODI) scores ( , , ). The outcomes with subgroup analysis showed that MSC therapy could decrease VAS scores in 3 months ( ), 6 months ( ), 12 months ( ), and ≥24 months ( ) and ODI scores in ≥24 months ( ). Pooled analysis showed that MSC therapy has a higher ratio of patients at most thresholds but particularly at the MIC (minimally important change) (